Initial combination therapy with vildagliptin plus metformin in drug-naïve patients with T2DM: a 24-week real-life study from Asia

References

• International Diabetes Federation. IDF Diabetes Atlas, 8 ed. Brussels, Belgium: International Diabetes Federation; 2017. Available at: http://www.diabetesatlas.org/resources/2017-atlas.html [Last accessed 8 January 2018]
   Google Scholar
• Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet 2010;375:408-18
   PubMed Web of Science ®Google Scholar
• Stark Casagrande S, Fradkin JE, Saydah SH, et al. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care 2013;36:2271-9
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2017 executive summary. Endocr Pract 2017;23:207-38
   PubMed Web of Science ®Google Scholar
• Zinman B. Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time? Am J Med 2011;124(1 Suppl):S19-34
   PubMed Web of Science ®Google Scholar
• Schweizer A, Couturier A, Foley JE, et al. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with type 2 diabetes. Diabet Med 2007;24:955-61
   PubMed Web of Science ®Google Scholar
• Bosi E, Dotta F, Jia Y, et al. Vildagliptin/metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009;11:506-15
   PubMed Web of Science ®Google Scholar
• WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:902
   PubMed Web of Science ®Google Scholar
• Rhee EJ. Diabetes in Asians. Endocrinol Metab (Seoul) 2015;30:263-9
   PubMedGoogle Scholar
• Cardiovascular disease – Risk factors. Available at: http://www.world-heart-federation.org/cardiovascular-health/cardiovascular-disease-risk-factors/ [Last accessed 8 January 2018]
   Google Scholar
• Joshi P, Islam S, Pais P, et al. Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA 2007;297:286-94
   PubMed Web of Science ®Google Scholar
• Pratley RE, Fleck P, Wilson C. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes Obes Metab 2014;16:613-21
   PubMed Web of Science ®Google Scholar
• Kadoglou NP, Kapelouzou A, Tsanikidis H, et al. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naive patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2011;119:63-8
   PubMed Web of Science ®Google Scholar
• Fajos MC, Lantion-Ang FL, Jimeno CA, et al. Complications and cardiovascular risk factors among newly-diagnosed type 2 diabetics in Manila. Phil J Intern Med 2009;47:99-105
   Google Scholar
• Sosale B, Sosale AR, Mohan AR, et al. Cardiovascular risk factors, micro and macrovascular complications at diagnosis in patients with young onset type 2 diabetes in India: CINDI 2. Indian J Endocrinol Metab 2016;20:114-18
   PubMedGoogle Scholar
• Shelbaya S, Rakha S. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt – results from the GUARD study. Curr Med Res Opin 2017;33:797-801
   PubMed Web of Science ®Google Scholar
• Lim S, An JH, Shin H, et al. Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study. Clin Endocrinol (Oxf) 2012;77:215-23
   PubMed Web of Science ®Google Scholar
• Lee YK, Song SO, Kim KJ, et al. Glycemic effectiveness of metformin-based dual-combination therapies with sulphonylurea, pioglitazone, or DPP4-inhibitor in drug-naïve Korean type 2 diabetic patients. Diabetes Metab J 2013;37:465-74
   PubMedGoogle Scholar
• Ku EJ, Jung KY, Kim YJ, et al. Four-year durability of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes in clinical practice; COSMIC study. PLoS One 2015;10:e0129477
   PubMed Web of Science ®Google Scholar
• Pan C, Xing X, Han P et al. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2012;14:737-44
   PubMed Web of Science ®Google Scholar
• Ratzinger M, Brath H, Kautzy-Willer A, et al. Glycaemic control is not affected by age and gender: results from a large cohort study (EDGE). P-274, Poster presented at the 49^th Annual Meeting of the EASD, 23–27 September 2013, Barcelona, Spain
   Google Scholar
• Bader G, Schweizer A, Foley J. Change in HbA1c after 24 weeks as a function of baseline HbA1c: comparison between vildagliptin and sulfonylureas in interventional clinical trials and real-life conditions. P-1160. Poster presented at the 73^rd Scientific Sessions of the American Diabetes Association (ADA), 21–25 June 2013, Chicago, IL, USA.
   Google Scholar
• Rosales R, Abou Jaoude E, Al-Arouj M, et al. Clinical effectiveness and safety of vildagliptin in >19 000 patients with type 2 diabetes: the GUARD study. Diabetes Obes Metab 2015;17:603-7
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
   PubMed Web of Science ®Google Scholar
• Watanabe T, Narukawa M. Characteristics of safety information obtained from postmarketing observational studies for re-examination in Japan. Springerplus 2016;5:905
   PubMedGoogle Scholar